Get the Stockscreener App
0.309
4.57%
0.0135
After Hours:
.28
-0.029
-9.39%
Sensei Biotherapeutics Inc stock is traded at $0.309, with a volume of 71,267.
It is up +4.57% in the last 24 hours and down -23.68% over the past month.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
See More
Previous Close:
$0.2955
Open:
$0.2955
24h Volume:
71,267
Relative Volume:
0.03
Market Cap:
$7.79M
Revenue:
-
Net Income/Loss:
$-29.80M
P/E Ratio:
-0.2597
EPS:
-1.19
Net Cash Flow:
$-25.19M
1W Performance:
-0.48%
1M Performance:
-23.68%
6M Performance:
-44.37%
1Y Performance:
-60.89%
1-Day Range:
$0.2955
$0.3233
1-Week Range:
$0.2625
$0.3444
52-Week Range:
$0.25
$0.88
Sensei Biotherapeutics Inc Stock (SNSE) Company Profile
Name
Sensei Biotherapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
0.309 | 7.83M | 0 | -29.80M | -25.19M | -1.19 |
|
ONC
Beigene Ltd Adr
|
238.31 | 25.61B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.00 | 114.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.26 | 41.82M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.26 | 66.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.61 | 6.36B | 0 | -153.72M | -103.81M | -2.00 |
Sensei Biotherapeutics Inc Stock (SNSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Jun-29-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Mar-01-21 | Initiated | Citigroup | Buy |
| Mar-01-21 | Initiated | Oppenheimer | Outperform |
| Mar-01-21 | Initiated | Piper Sandler | Overweight |
View All
Sensei Biotherapeutics Inc Stock (SNSE) Latest News
VISTA Inhibitor Clinical Trials Market Insights and Drug Development Opportunities Report 2025-2028 Featuring Aurigene, Curis, Hummingbird Bioscience, Kineta, PharmAbcine, Sensei BiotherapeuticsResearchAndMarkets.com - FinancialContent
Sensei Biotherapeutics stockholders approve key proposals By Investing.com - Investing.com Nigeria
Sensei Biotherapeutics stockholders approve key proposals - Investing.com
Sensei Biotherapeutics Approves Reverse Stock Split - TipRanks
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Shares Sold by Renaissance Technologies LLC - Defense World
Sensei Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sensei (SNSE) Reports Encouraging Clinical Results in Recent Qua - GuruFocus
Sensei Biotherapeutics Reports Promising Q1 2025 Results - TipRanks
Sensei Biotherapeutics Reports First Quarter 2025 Financial Resu - GuruFocus
Sensei (SNSE) Reports Encouraging Clinical Results in Recent Quarter | SNSE Stock News - GuruFocus
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress - The Manila Times
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress | SNSE Stock News - GuruFocus
Sensei Bio's Cancer Drug Achieves Breakthrough: 3X Better Response in PD-L1 Resistant Patients - Stock Titan
Sensei Biotherapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
SEC Form DEF 14A filed by Sensei Biotherapeutics Inc. - Quantisnow
Penny Stocks To Add to Your WatchlistMarch 30th - MarketBeat
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - The Manila Times
Promising Penny Stocks To ResearchMarch 29th - MarketBeat
Best Penny Stocks To Follow NowMarch 28th - MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Sensei Biotherapeutics stock hits 52-week low at $0.34 By Investing.com - Investing.com South Africa
Sensei Biotherapeutics stock hits 52-week low at $0.34 - Investing.com
HC Wainwright Reiterates Buy Rating for Sensei Biotherapeutics (NASDAQ:SNSE) - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Price Target Raised to $4.00 at Oppenheimer - Armenian Reporter
Sensei Biotherapeutics Reports Promising 2024 Results - TipRanks
Sensei Biotherapeutics (SNSE) Reports Annual Loss and Decline in Cash Reserves - GuruFocus
Sensei stock holds Buy rating, $4 target from H.C. Wainwright By Investing.com - Investing.com Australia
Sensei Rockets on FY ’24 Results - Baystreet.ca
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors - Benzinga
Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer - TipRanks
Oppenheimer Adjusts Price Target on Sensei Biotherapeutics to $4 From $3.50, Maintains Outperform Rating - Marketscreener.com
Sensei Biotherapeutics reports FY24 EPS ($1.20) vs ($1.22) last year - TipRanks
Sensei stock holds Buy rating, $4 target from H.C. Wainwright - Investing.com
Sensei Biotherapeutics Inc Cash Runway Into Q2 Of 2026 - MarketScreener
Sensei Biotherapeutics, Inc. SEC 10-K Report - TradingView
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress - GlobeNewswire
Breakthrough: Sensei's Cancer Drug Triples Response Rate in Hard-to-Treat Tumors - Stock Titan
Sensei Biotherapeutics announces initial results from solnerstotug trial portion - TipRanks
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data For Solnerstotug In PD-(L)1 Resistant Tumors - Marketscreener.com
Sensei Biotherapeutics : Company Presentation March 2025 - Marketscreener.com
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors - GlobeNewswire
Revolutionary Cancer Treatment Triples Response Rate in Hard-to-Treat Tumors: Clinical Trial Results Revealed - Stock Titan
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Large Drop in Short Interest - Defense World
Sensei Biotherapeutics Stock Price, Quotes and Forecasts | NASDAQ:SNSE - Benzinga
Sensei Biotherapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Sensei Biotherapeutics (SNSE) to Release Quarterly Earnings on Wednesday - Defense World
What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock - MSN
A stock that deserves closer examination: Sensei Biotherapeutics Inc (SNSE) - US Post News
Sensei Biotherapeutics Inc Stock (SNSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):